Z-VEID-FMK: Irreversible Caspase-6 Inhibitor for Apoptosis and Disease Models

Executive Summary: Z-VEID-FMK (CAS 210344-96-0) is a cell-permeable, irreversible peptide-based inhibitor targeting caspase-6, a cysteine protease central to apoptosis regulation. This fluoromethyl ketone compound covalently binds the caspase-6 active site, blocking its proteolytic function and downstream substrate cleavage (APExBIO). It is validated at >94% purity using HPLC, MS, and NMR. Z-VEID-FMK is widely used at 50 μM for 6-hour cell culture incubations to dissect caspase-6-dependent pathways, especially in neuronal and immune cell apoptosis models (Z-VEID-FMK: Precision Caspase-6 Inhibition in Apoptosis Research). This inhibitor is insoluble in water, dissolves in DMSO (≥113.4 mg/mL) and ethanol (≥3.01 mg/mL), and must be stored at -20°C for stability. Z-VEID-FMK is essential for studying caspase-6 roles in apoptosis, neurodegeneration, and cancer (Padia et al., 2025).

Biological Rationale

Caspase-6 is a cysteine-aspartic protease involved in the execution phase of apoptosis. It cleaves nuclear lamins and cytoskeletal proteins, regulating nuclear morphology during programmed cell death (Padia et al., 2025). Dysregulation of caspase-6 activity has been implicated in neurodegenerative diseases (e.g., Alzheimer's, Huntington's) and various cancers. Inhibition of caspase-6 allows researchers to delineate its role in apoptosis, particularly in contexts where caspase-6 activity intersects with pyroptosis and other cell death pathways. Precise inhibition provides mechanistic clarity in complex models where multiple caspases and death modalities may overlap (Expanding the Frontiers of Apoptosis and Caspase-6 Inhibition).

Mechanism of Action of Z-VEID-FMK

Z-VEID-FMK is a tetrapeptide fluoromethyl ketone derivative with the sequence Z-Val-Glu-Ile-Asp(OMe)-FMK. This sequence mimics the preferred substrate recognition motif for caspase-6. The fluoromethyl ketone reactive group forms a covalent bond with the catalytic cysteine in the caspase-6 active site, resulting in irreversible inhibition (APExBIO). The cell-permeable design ensures rapid intracellular delivery. Irreversible inhibition distinguishes Z-VEID-FMK from reversible peptide aldehyde-based inhibitors, ensuring persistent blockade during experimental windows. This enables reliable measurement of caspase-6-dependent events, such as substrate cleavage and nuclear lamina breakdown, with minimal off-target effects at recommended concentrations.

Evidence & Benchmarks

• Z-VEID-FMK inhibits recombinant human caspase-6 activity in vitro with nanomolar potency (IC₅₀ typically <1 μM) under standard buffer conditions (25°C, pH 7.4) (APExBIO).
• In neuronal cell apoptosis assays, 50 μM Z-VEID-FMK blocks nuclear lamina cleavage and protects against staurosporine-induced apoptosis over 6 hours (Z-VEID-FMK: Precision Caspase-6 Inhibition in Apoptosis Research).
• Cellular uptake and inhibitory effect persist for at least 6 hours post-addition, with no cytotoxicity at ≤50 μM in standard culture (Expanding the Frontiers of Apoptosis and Caspase-6 Inhibition).
• Z-VEID-FMK is validated at >94% purity by HPLC, mass spectrometry (ESI-MS), and NMR, ensuring batch-to-batch consistency (APExBIO).
• In disease models, Z-VEID-FMK enables selective dissection of caspase-6-dependent versus caspase-1-mediated pyroptosis pathways, as shown in lung tumorigenesis and immune cell death models (Padia et al., 2025).

Common Pitfalls or Misconceptions

• Not a pan-caspase inhibitor: Z-VEID-FMK is selective for caspase-6 and does not effectively inhibit caspase-1, -3, or -8 at standard concentrations.
• Not soluble in water: Direct aqueous dissolution leads to precipitation; always dissolve in DMSO or ethanol.
• Irreversible action: Inhibition cannot be reversed by washing or dilution; irreversible binding persists for the duration of the experiment.
• Short-term stability: Stock solutions stored above -20°C or for prolonged periods may degrade, losing activity.
• No effect on non-apoptotic cell death: Z-VEID-FMK does not inhibit necroptosis or non-caspase-6-dependent pyroptosis.

Applications, Limits & Misconceptions

Applications: Z-VEID-FMK is widely used in research on apoptosis, especially for dissecting the role of caspase-6 in neuronal and immune cell models. It is essential for distinguishing caspase-6-dependent apoptosis from pyroptosis and other death pathways, enabling high-resolution analysis in neurodegeneration and cancer models (Padia et al., 2025). The inhibitor is also useful in mechanistic studies of caspase signaling cascades and in benchmarking new apoptosis assays. In contrast to pan-caspase inhibitors, Z-VEID-FMK provides target specificity, reducing off-target effects. For a detailed comparison of workflow strategies, see Z-VEID-FMK: Redefining Caspase-6 Inhibition in Disease Models, which explores mechanistic advances beyond this article's focus on application boundaries.

Limits: Z-VEID-FMK does not inhibit other caspase family members or non-caspase proteases. It is not effective in models where apoptosis is independent of caspase-6. High concentrations (>100 μM) may introduce off-target effects. The compound is not suitable for in vivo use without further pharmacokinetic validation. It should not be used for long-term cell culture studies due to irreversible inhibition and potential accumulation of inactivated enzyme-adduct complexes. For advanced translational guidance, see Translational Precision: Strategic Integration of Irreversible Caspase Inhibitors, which extends this overview by examining clinical translation challenges.

Workflow Integration & Parameters

Stock Preparation: Dissolve Z-VEID-FMK in DMSO (≥113.4 mg/mL) or ethanol (≥3.01 mg/mL) with gentle warming and ultrasonic treatment. Filter sterilize if used for cell culture. Store aliquots at -20°C for up to 6 months.

Experimental Use: Add to cell culture at 50 μM final concentration. Incubate for 6 hours at 37°C. For caspase activity assays, pre-incubate cells prior to inducing apoptosis (e.g., with TNFα or Fas ligand). Do not exceed 0.1% DMSO in final media to avoid solvent toxicity. After use, dispose of solutions according to institutional chemical safety guidelines.

Shipping and Handling: Z-VEID-FMK is shipped on blue ice to preserve stability. Warm to room temperature before opening vials to avoid condensation.

Benchmarking: Always include appropriate vehicle and apoptosis controls. Validate inhibition by monitoring cleavage of known caspase-6 substrates (e.g., nuclear lamins) via immunoblot or activity-based probes. For comprehensive experimental design principles, see Z-VEID-FMK: Precision Caspase-6 Inhibitor for Apoptosis Assays, which provides expanded protocols and troubleshooting tips not detailed here.

Conclusion & Outlook

Z-VEID-FMK, as provided by APExBIO, is a rigorously validated, high-purity, irreversible, cell-permeable caspase-6 inhibitor. It is indispensable for precise delineation of caspase-6-dependent apoptosis in disease models, enabling mechanistic and translational research in neurodegeneration and cancer. While it is not a pan-caspase inhibitor and is unsuitable for long-term or in vivo studies, its specificity and well-characterized performance make it the gold standard for caspase-6 pathway interrogation. Future research will benefit from integrating Z-VEID-FMK with new imaging, omics, and activity-based probe technologies to further unravel the complexities of cell death signaling (Padia et al., 2025).